anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The patients will undergo standard assisted conception procedures; controlled ovarian stimulation (COS), oocyte pickup procedure (OPU), ICSI, embryo culture, blastocyst vitrification and frozen embryo transfer. If sufficient (\>2) viable blastocyst develop from the in vitro culture of their embryos, all viable blastocysts will be cryopreserved using a routine vitrification procedure. This is the eligible patient population. On the day the last blastocyst(s) are frozen the patients will be given a further opportunity to ask questions and if satisfied they will be asked to complete a trial consent. At this point patients will be randomized by numeric code and given a schedule and drug prescription for scheduling the start of their hormone supplemented frozen embryo transfer cycle. During the scheduling period the patients will follow the drug prescription provided . After the completion of their treatment - the transfer of one or two vitrified-warmed blastocyst - the patients from both groups will receive identical luteal support drug schedules and prescriptions. A blood test will be performed on the 15th day of progesterone supplementation, to determine the βhCG blood concentration. Currently at Antalya IVF, approximately 75% of patients who have blastocysts transferred in a frozen embryo transfer cycle have a positive biochemical pregnancy test, \>29 international units per litre (IU/L) of human chorionic gonadotropin (βhCG). If pregnant, patients will continue using estrogen and progesterone supplementation for a further 8 weeks. At 7 weeks of gestation (5 weeks after embryo transfer ) the patients will receive a transvaginal ultrasound scan (TVUS) to check for pregnancy viability (fetal sac with cardiac activity). Thereafter the patients will have regular TVUS to follow fetal development. At 20 weeks of gestation a TVUS will be performed to confirm an ongoing pregnancy (normal fetal development).

All drug packs are delivered to the clinic by the pharmacy after receiving the prescription. A staff member will verify the code on the prescription with randomization code allocated to the patient. The pack will then be given to the patient after verbally confirming patient identity. The packs will also contain a drug use instruction sheet and a trial information sheet.
PCT No. PCT/EP94/03448 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Oct. 20, 1994 PCT Pub. No. WO95/11005 PCT Pub. Date Apr. 27, 1995The present invention relates to hydrous, liquid, paste- or cream-like skin cleaning agents for the removal of strongly adhering soil, comprising anionic and/or amphoteric and/or non-ionogenic surfactants as washing-active substances, thickeners, at least one abrasive, and, optionally, adjuvants for the regulation of consistency, appearance, odor, and stability, such as pigments, fragrances, stabilizers, and preservatives, which skin cleaning agents are characterized by the fact that they comprise di-n-butyl adipate and/or diisopropyl adipate as the exclusive solvents. These agents are obtained by homogeneously mixing the components, optionally under heating of the mixture. If a C8-C16 fatty alcohol which acts as consistency regulator is added, heating of the component mixture may be omitted. Besides, the addition of the fatty alcohol increases the detergent action. The present invention further relates to the use of these skin cleaning agents, with the cleaning agent being distributed on the skin without water or with a small amount of water first, and the cleaning procedure being continued and finished under rinsing with water.
OBJECTIVE: This study aimed to analyze the impact of HGF on cardiomyocyte injury, apoptosis, and inflammatory response induced by lipopolysaccharide (LPS).
METHODS: Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify the levels of HGF, interleukin (IL)-6, IL-10, creatine phosphokinase-isoenzyme-MB (CK-MB), and cardiac troponin I (cTnI) in the samples. qPCR and Western blotting (WB) were employed to assess the mRNA and protein expressions of HGF, IL-10, IL-6, PI3K, AKT, p-PI3K, and p-AKT.
RESULTS: The outcomes of the in vivo experiment revealed that serum levels of IL-6, IL-10, HGF and SOFA scores in the SC group were elevated in contrast to the non-SC group. The correlation analysis indicated a substantial and positive association among serum HGF, IL-6, and IL-10 levels and SOFA scores. Relative to IL-6, IL-10 levels, and SOFA scores, serum HGF demonstrated the highest diagnostic value for SC. Following LPS administration to stimulate H9c2 cells across various periods (0, 12, 24, 48, and 72 h), the levels of myocardial injury markers (CK-MB and cTnI) in the cell supernatants, intracellular inflammatory factors (mRNA and protein levels of IL-10 and IL-6), apoptosis and ROS levels, exhibited a gradual increase followed by a subsequent decline. Following the overexpression of HGF, there was an increase in cell viability, and a decrease in apoptosis, inflammation, oxidative stress injuries, and the protein phosphorylation expressions of PI3K and AKT. After knockdown of HGF expression, the activity of LPS-induced H9c2 cells was further reduced, leading to increased cell injury, apoptosis, inflammation, oxidative stress,and the expression levels of PI3K and Akt protein phosphorylation were further elevated.
CONCLUSION: HGF was associated with decreased LPS-induced H9c2 apoptosis and inflammation in H9c2 cells, alongside an improvement in cell viability, indicating potential cytoprotective effects. The mechanism underlying these impacts may be ascribed to the suppression of the PI3K/AKT signaling pathway.
For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.
BACKGROUND: New and persistent opioid use after minor and major surgery is common, and the duration of opioid use following surgery is associated with opioid dependence, abuse, and overdose. Most patients undergoing thyroid or parathyroid surgery do not require opioid discharge prescriptions for effective pain management. If opioids are prescribed for these surgeries, up to 7% of patients will use opioids 3 to 6 months after surgery. Previously published quality programs that optimized perioperative multimodal analgesia (MMA) regimens, provider education, patient education, and shared decision making successfully reduced the proportion of patients discharged with opioid prescriptions to less than 5% following thyroid and parathyroid surgery.

STUDY DESIGN: This quasi-experimental, quality improvement study compares opioid discharge prescribing practices before and after implementation of the quality improvement bundle. The quality improvement bundle includes patient education, provider education, and EHR enhancements. Patients who undergo a thyroidectomy or parathyroidectomy procedure will be included in the study. The historical control group includes patients treated prior to bundle implementation. The post-implementation group includes patients treated within 4 to 6 months following bundle implementation. The primary outcome is the proportion of patients who receive new opioid discharge prescriptions at discharge following a thyroidectomy or parathyroidectomy procedure. This outcome excludes the continuation of previous, chronic opioid therapy.
PURPOSE: A wound dressing of gel type introduces carboxyl group into polyurethane to improve bio-adaptation by decreasing hydrophilicity, and to enhance aeration, the absorption of moisture and the absorption of discharge from the wound. CONSTITUTION: Polypropylene glycol is heated at 60°C. for 30 minutes then 100 g of methylene di-p-phenyl diisocyanate per hour is added thereto and mixed therewith at 70°C. to prepare polyurethane. Carboxyl group of 0.5-10wt.% of dimethyl propionic acid, 0.5-10wt.% of dimethyloylbutanoic acid, 0.5-5wt.% of alginate, 0.5-5wt.% of hyaluronic acid or 0.5-5wt.% of mixture of alginate and hyaluronic in the ratio of 1:1, 1.2 wt.% of surfactant and 5wt.% of foaming agent are added at room temperature and under atmospheric pressure in order to prepare polyurethane foam which is hydrogel type and can be used for wound dressing. The surfactant used is L-5305 of a silicone surfactant.
Identity

No. 1000, GLOFIL-125 is a clear, colorless, sterile, and nonpyrogenic solution available as a 4 mL vial. It is supplied in a concentration of approximately 1 mg/mL sodium iothalamate (range is 0.5–2.0 mg sodium iothalamate per mL), with a radioactivity concentration of 250 to 300 μCi/mL at the time of calibration. Benzyl alcohol 0.9%, is added as a preservative. Sodium bicarbonate and hydrochloric acid are added for pH adjustment. The calibration and expiration dates are shown on the label.
Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
Repeated red cell transfusions lead to transfusional iron overload because the body lacks an efficient mechanism to excrete excess iron. Without treatment, iron accumulates in the liver, heart and endocrine glands. Cardiac complications including arrhythmias and congestive heart failure are the most common cause of death from transfusional iron overload. New magnetic resonance imaging (MRI) T2\* techniques enable an estimation of cardiac iron loading, and allow patients at the highest risk of cardiac disease (those with T2\* \< 10 ms) to be identified. For over 30 years, deferoxamine has been the standard therapy. However, the mode of administration is cumbersome (subcutaneous or intravenous infusion over 8 to 12 hours daily), leading to poor compliance. Thus, cardiac disease and early mortality continue to be a significant problem in patients treated with chronic transfusions. Treatment of cardiac complications involves intensifying therapy with deferoxamine, including recommending intravenous administration over a period of 24 hours daily. Deferiprone is an oral chelating agent, not FDA approved for use in the United States. Recent studies indicate that deferiprone is superior to deferoxamine in removing cardiac iron and reducing iron-induced cardiotoxicity. The most serious side effect of deferiprone is agranulocytosis, and other side effects are gastrointestinal symptoms, reversible arthralgia, reddish discoloration of urine and rare cases of autoimmune disease. Patients on the study will be closely monitored for these toxicities. Patients who are currently regularly followed at The Children's Hospital of Philadelphia will be prescribed deferiprone at 75 mg/kg/day in three divided doses, taken orally, in combination with deferoxamine, at the patient's current dose. Labs will be drawn once per week to monitor neutrophil count, with additional labs every three months to monitor ferritin and ALT levels.
The investigators will employ a quasi-experimental study design to test two hypotheses: H1: SMM rates among Black people will decline after the interventions (equity payment and obstetric bundled payment), relative to people of other race groups within Pennsylvania (PA); and H2: Racial inequities in SMM will decline among those exposed to the interventions in PA, relative to those in similar states. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare interventions on beneficiaries' experiences.
OBJECTIVE: The goal of the present study was to examine teachers' perceptions of neuropsychological reports broadly and their preparedness to support the educational needs of students with chronic health conditions.
METHOD: Teachers were selected from across the United States using stratified random sampling. 280 teachers (76.2% female; 58.4% public school; 53.9% rural setting) completed an anonymous electronic survey via Qualtrics.
RESULTS: Half of the teachers were familiar with neuropsychology and previously read a neuropsychological report, which the majority found useful with a preference toward shorter reports. Most found listed recommendations to be appropriate, but half of teachers identified limited resources as a barrier to implementation. Teachers reported limited education, training, and comfort for providing accommodations to children with chronic health conditions, which was significantly lower for cancer, congenital heart disease, and sickle cell disease. Older teachers, more years of experience, and special education teachers demonstrated significantly higher levels of education, training, and comfort. Frequency of implementing accommodations was significantly negatively correlated with perceived burden and positively correlated with perceived benefit across most accommodations. Teachers reported a preference for single-page handouts and speaking directly to neuropsychologists about the specific learning needs of students with chronic health conditions.
CONCLUSIONS: Results highlight areas for future research and intervention regarding teacher's preparedness for working with children with chronic health groups and opportunities to improve communication between neuropsychologists and teachers to ultimately improve access to educational supports and overall quality of life of students with chronic health conditions.
INTRODUCTION: Neurodevelopmental disorders (NDDs) refer to a broad range of diseases including developmental delay, intellectual disability, epilepsy, autism spectrum disorders, and attention-deficit/hyperactivity disorder caused by dysfunctions in tightly controlled brain development. The genetic backgrounds of NDDs are quite heterogeneous; to date, recessive or dominant variations in numerous genes have been implicated. Herein, we present a large consanguineous family from Turkiye, who has been suffering from NDDs with two distinct clinical presentations.
METHODS AND RESULTS: Combined in-depth genetic approaches led us to identify a homozygous frameshift variant in NALCN related to NDD and expansion of dodecamer repeat in CSTB related to Unverricht-Lundborg disease (ULD). Additionally, we sought to functionally analyze the NALCN variant in terms of mRNA expression level and current alteration. We have both detected a decrease in the level of premature stop codon-bearing mRNA possibly through nonsense-mediated mRNA decay mechanism and also an increased current in patch-clamp recordings for the expressed truncated protein.
CONCLUSION: In conclusion, increased consanguinity may lead to the revealing of distinct rare neurogenetic diseases in a single family. Exome sequencing is generally considered the first-tier diagnostic test in individuals with NDD. Yet we underline the fact that customized approaches other than exome sequencing may be used as in the case of ULD to aid diagnosis and better genetic counseling.
Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
Burn injury patients undergo a series of metabolic events that, if untreated, could lead to severe physical impairment and even death. Antioxidants minimize free radical damage by neutralizing the chemical reaction as well as promoting cellular repair. Currently there is no consistent protocol for micronutrient repletion in adult burn patients. The aim of this study is to evaluate the effectiveness of the current vitamin regimen in comparison to the novel vitamin and mineral supplementation protocol developed by the research team. Dosages for oral and intravenous supplementation are based on current literature. The combination of intravenous and enteral treatment is important due to gastrointestinal mucosal swelling related to post-burn fluid resuscitation. Measurable health outcomes will include rate of infection, length of hospital stay, mortality rate, hospital cost, number of days in intensive care unit, number of ventilator-dependent days and wound healing. The investigators hypothesize that use of the novel vitamin and mineral supplement regimen will improve adult burn patient outcomes.
Nateglinide Tablets, USP are an oral antidiabetic agent used in the management of Type 2 diabetes mellitus [also known as non-insulin dependent diabetes mellitus (NIDDM) or adult-onset diabetes]. Nateglinide,(-)-N-[(trans-4-isopropylcyclohexane)carbonyl]-D-phenylalanine, is structurally unrelated to the oral sulfonylurea insulin secretagogues.

The structural formula is as shown

Nateglinide is a white powder with a molecular weight of 317.43. It is freely soluble in methanol, ethanol, and chloroform, soluble in ether, sparingly soluble in acetonitrile and octanol, and practically insoluble in water. Nateglinide biconvex tablets contain 60 mg, or 120 mg, of nateglinide for oral administration.

Inactive Ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch. The 60 mg also contains iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. In addition, the 120 mg contains FD&C Yellow #6/Sunset Yellow Aluminum Lake, iron oxide yellow.
The invention relates to a rapid traditional Chinese medicine treatment method and an implementation method thereof. According to the method, Chinese medicinal material selection, medicine preparation and medicine use are carried out based on traditional medicinal compatibility of Chinese medicines, thus realizing the purpose of rapid disease removal. The rapid traditional Chinese medicine treatment method is characterized by comprising the following pathological characteristic and medical technology. The pathological characteristic shows that the pathological manifestations and pain points can be found at specific positions. According to the technological characteristic, body surface diseases can show phased improvement within 5-30min; for internal diseases, if medication is applied in the morning, the diseases can be alleviated at about 5 o'clock in the afternoon; and if medication is applied before 5 o'clock in the afternoon, the diseases can be alleviated before 11 o'clock at night. The medical technology includes: digestion and separation of pure substances from turbid ones in the traditional Chinese medicine are adopted as the main technical means; a formulation principle of monarch, minister, assistant and guide and targeted medication methods are employed. The targeted rapid treatment methods include: medicine preparation and administration methods for treatment of sore throat or quinsy; medicine preparation and administration methods for treatment of bronchitis and acute pneumonia; medicine preparation and administration methods for treatment of raccoon eyes and under-eye puffiness; medicine preparation and administration methods for treatment of myopia, glaucoma and ocular hypertension.
The invention belongs to the field of microorganisms and pet health products, and provides lactobacillus plantarum, a pet health product and a using method thereof. The preservation number of the Lactobacillus plantarum (Lactobacillus plantarum) is CGMCC No. 24558. The pet health product comprises the bacterial powder of the lactobacillus plantarum. The product of the invention has good effects of reducing the content of helicobacter pylori and increasing the quantity of bifidobacteria in intestinal tracts for cats and dogs, and can improve the intestinal health of pets. The pet health care product which is prepared by matching the feed additive with the specific components has a synergistic effect, can assist in treating intestinal diseases of pets, reduce the number of helicobacter pylori in the bodies of the pets, increase the number of beneficial bacteria in the intestinal tracts, remarkably improve the intestinal health of the pets, reduce diarrhea, promote fat digestion and utilization, regulate fat metabolism function and improve the digestive function of the pets.
The invention discloses a postoperative drug for chronic peptic ulcer and esophagitis syndrome. The drug is applied to the postoperative treatment of chronic peptic ulcer and esophagitis syndrome. The drug is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: litchi chinensis Sonn., lindernia ruellioides (Colsm.)Pennell, polygonum orientale L., radix platycodi, aeschynomene indica L., trachelospermum jasminoides (Lindl.) Lem., radix puerariae, paris polyphylla Sm., luffa cylindrica (L.) Roem., manis pentadactyla Linnaeus, hordeum vulgare L. and setaria italica (L.) Beauv.. Proved by clinical trials, the drug has the characteristics of low recurrence rate and high safety in the postoperative treatment of chronic peptic ulcer and esophagitis syndrome, so that the method is worthy of clinical application and popularization.
For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
The utility of current recombinant adenovirus vectors for gene therapy applications is improved by designing targeted vectors capable of gene delivery to selected cell types in vivo. In order to achieve such targeting, incorporation of ligands in the adenoviral fiber protein, in which the protein mediates primary binding of adenovirus to its cell surface receptor, utilizes the HI loop of the fiber knob as a convenient locale for incorporation of heterologous ligands. Recombinant fiber proteins expressed in a variety of cells including baculovirus-infected insect cells and E. coli to demonstrate that the incorporation of the FLAG octapeptide into the HI loop does not ablate fiber trimerization and does not disturb formation of the cell-binding site localized in the knob. A recombinant adenovirus of the instant invention having this modified fiber shows that a short peptide sequence engineered in the knob is compatible with the biological functions of the fiber. A peptide incorporated into the knob according to the invention remains available for binding in the context of mature virions containing modified fibers. The invention incorporates heterologous ligands into the HI loop of the fiber knob and the properties of this locale are consistent with its employment in adenovirus retargeting strategies.
Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.